BioWorld

June 22, 2005

Genaissance, Diagnostics Firm Plan To Merge In $56M Deal

In a bid to fuse diagnostics with pharmacogenomics, Clinical Data Inc. is taking over Genaissance Pharmaceuticals Inc. in an all-stock deal valued at about $56 million. (BioWorld Today) Read More

Inex Cuts More Employees; Cash Will Last Into Next Year

BIO Leaders Point Toward Fresh Lobbying, Public Outreach Efforts

Officer's Death During Protest Mars Convention On Tuesday

Education, Respect Needed To Improve Image of Biotech

Correction

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...